Abvc Biopharma Stock Today
| ABVC Stock | USD 0.78 0.01 1.65% |
Performance0 of 100
| Odds Of DistressOver 85
|
ABVC Biopharma is trading at 0.777 as of the 7th of June 2024, a -1.65% down since the beginning of the trading day. The stock's open price was 0.79. ABVC Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for ABVC Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of May 2024 and ending today, the 7th of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2017 | Category Healthcare | Classification Health Care |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 10.85 M outstanding shares of which 587.59 K shares are presently shorted by private and institutional investors with about 0.4 trading days to cover. More on ABVC Biopharma
Moving together with ABVC Stock
Moving against ABVC Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ABVC Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ABVC Biopharma's financial leverage. It provides some insight into what part of ABVC Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC Biopharma (ABVC) is traded on NASDAQ Exchange in USA. It is located in 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538 and employs 16 people. ABVC Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.56 M. ABVC Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.85 M outstanding shares of which 587.59 K shares are presently shorted by private and institutional investors with about 0.4 trading days to cover.
ABVC Biopharma currently holds about 2.99 M in cash with (4.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check ABVC Biopharma Probability Of Bankruptcy
Ownership AllocationABVC Biopharma retains substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check ABVC Ownership Details
ABVC Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Chase Investment Counsel Corp | 2024-03-31 | 178.4 K | |
| Vanguard Group Inc | 2024-03-31 | 46.9 K | |
| Renaissance Technologies Corp | 2023-12-31 | 36.1 K | |
| Geode Capital Management, Llc | 2024-03-31 | 22 K | |
| Bank Of America Corp | 2024-03-31 | 4.4 K | |
| Tower Research Capital Llc | 2023-12-31 | 578 | |
| Spotlight Asset Group, Inc. | 2024-03-31 | 100.0 | |
| Wells Fargo & Co | 2024-03-31 | 48.0 | |
| Royal Bank Of Canada | 2024-03-31 | 37.0 | |
| Jpmorgan Chase & Co | 2023-12-31 | 0.0 | |
| Virtu Financial Llc | 2023-12-31 | 0.0 |
ABVC Biopharma Historical Income Statement
ABVC Stock Against Markets
ABVC Biopharma Corporate Management
| TsungShann Jiang | Member Officer | Profile | |
| Leeds Chow | Chief Officer | Profile | |
| Howard MD | Pres CEO | Profile | |
| ChiHsin King | Chief Officer | Profile | |
| Uttam Patil | Chief Officer | Profile | |
| Eugene Jiang | Chairman Officer | Profile |
Already Invested in ABVC Biopharma?
The danger of trading ABVC Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ABVC Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ABVC Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ABVC Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Information and Resources on Investing in ABVC Stock
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share 0.004 | Quarterly Revenue Growth (0.99) | Return On Assets (0.48) | Return On Equity (2.82) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.